| Patient | Pierre Le Moyne d'Iberville |
|---|---|
| Date of birth | 1661-07-16 |
| Identifiers | MRN HR-ET014-SYN-TD; SSN (made up) 000-14-7260 |
| Document date | 1705-03-31 |
| Author | Marguerite Delacroix-Boateng, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week review after chloroquine and primaquine. [S]
Mr. Le Moyne d'Iberville returns four weeks after starting treatment. He took all four doses of chloroquine, with mild nausea on the first day, and finished the 14 days of primaquine two weeks ago, taking it with food; he had mild stomach cramps for a few days and no dark urine, breathlessness or blue lips. He has had no fever. He did not have the smear and PCR that were meant for a week after the last primaquine dose, because the date was not booked. He explained the fever plan back correctly. [S]
| Element | Detail |
|---|---|
| Chloroquine | All doses taken; mild nausea on the first day |
| Primaquine | 14 days completed two weeks ago; mild stomach cramps |
| Fever | None |
| Missed test | Post-treatment smear and PCR not done |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever or chills; energy better |
| Gastrointestinal | Negative | Cramps settled; no jaundice |
| Genitourinary | Negative | No dark urine |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Chloroquine phosphate 500 mg tablet: 1,000 mg (two tablets) at once, then 500 mg at 6, 24 and 48 hours; take with food | 1,000 mg, then 500 mg at 6, 24 and 48 hours (2,500 mg salt in total) | Oral route | 1705-03-03 to 1705-03-05 | completed | S |
| Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) by mouth daily with food for 14 days | 30 mg base once daily for 14 days | Oral route | 1705-03-03 to 1705-03-16 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1705-03-31 | Body height | 175 | cm | S |
| 1705-03-31 | Body weight | 69 | kg | S |
| 1705-03-31 | Body mass index (BMI) [Ratio] | 22.5 | kg/m2 | S |
| 1705-03-31 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1705-03-31 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1705-03-31 | Heart rate | 66 | /min | S |
| 1705-03-31 | Respiratory rate | 14 | /min | S |
| 1705-03-31 | Body temperature | 36.6 | Cel | S |
| 1705-03-31 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1705-03-31 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.2-17.1 g/dL | Normal | S |
| 1705-03-31 | Platelets [#/volume] in Blood by Automated count | 212 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1705-03-31 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.3-1.2 mg/dL | Normal | S |
Vital signs recorded on 1705-03-31; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; temperature 36.6 C, blood pressure 122/78, pulse 66, weight 69.0 kg |
| Eyes | No pallor; sclerae white |
| Skin | No cyanosis |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent episodes of fever with shaking chills and drenching sweats, three in the past two years, each beginning months after naval service in malaria-endemic areas; the first diagnosed as malaria abroad on a blood smear with the species not recorded and treated with chloroquine alone, the later two treated with chloroquine without testing; the last ended six weeks before intake; afebrile and well at intake; cause not established at intake; infectious diseases consultation requested | resolved | confirmed | R50.9 | S — Synthetic presenting problem anchored to his documented recurrent attacks of illness called malaria; superseded by the diagnosis at the infectious diseases consultation. |
| Relapsing Plasmodium vivax malaria: P. vivax DNA detected by PCR in blood drawn between attacks, with negative smears and rapid antigen test; after three relapses treated without antirelapse therapy; normal quantitative G6PD | resolved | confirmed | B51.9 | S — Synthetic modern diagnosis made at the infectious diseases consultation, linked to his documented recurrent attacks of illness called malaria; the species and the PCR result are synthetic. |
| Pre-travel care for a naval deployment, expected to sail early next year, to French Guiana and the French Antilles: yellow fever vaccination required for entry to French Guiana, malaria prevention, dengue, chikungunya and typhus prevention by vector avoidance, food and water safety, and travel vaccines | active | confirmed | Z71.84 | S — Synthetic modern counterpart of his documented preparation of a tropical campaign in 1705. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Blood count and bilirubin for hemolysis on primaquine | Baseline, then after the course | Completed today | Hemoglobin 13.6 g/dL, platelets 212 x10^3/uL, bilirubin 0.7 mg/dL: no hemolysis |
| Laboratory | Follow-up blood smear after treatment (ideally within one week of finishing) | About one week after finishing | Completed today | Smear negative today; PCR sent. Protocol deviation: the smear and PCR ordered for one week after the last primaquine dose were not drawn, because no date was booked; they were drawn today, two weeks after finishing. No harm resulted: the smear is negative and he has had no fever. Corrective action: book post-treatment tests with a date when treatment starts |
| Medication safety | Adverse effects: nausea, abdominal pain, dark urine, breathlessness, cyanosis | During the course | Completed today | Mild nausea on chloroquine and mild cramps on primaquine; no dark urine or cyanosis |
| Medication safety | Adherence to the full course | At the end of the course | Completed today | All doses of both medicines taken |
| Self-management | Relapse surveillance and the fever action plan | Every visit | Completed today | No fever; explained the plan back correctly |
Goal progress:
Guideline basis: Treatment of Uncomplicated Malaria (clinical guidance) (2026); CDC Yellow Book: Health Information for International Travel, 2026 edition. Malaria (2026)
Follow-up: Preventive visit in three weeks. Pre-travel visit in the summer. Next scheduled visit 1705-04-21: periodic adult preventive visit. [S]